These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32865771)

  • 1. Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database.
    Monaghan TF; Flores VX; Suss NR; Robins DJ; Smith MT; McNeil BK; Hyacinthe LM; Weiss JP; Winer AG
    Int Urol Nephrol; 2021 Feb; 53(2):235-239. PubMed ID: 32865771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
    World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
    Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
    Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of neoadjuvant chemotherapy for urothelial muscle-invasive bladder cancer: Does location matter?
    Monaghan TF; Robins DJ; Suss NR; Miller CD; Flores VX; Smith MT; Weiss JP; McNeil BK; Winer AG
    Int J Clin Pract; 2021 Aug; 75(8):e14262. PubMed ID: 33887115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Income Disparities in Survival and Receipt of Neoadjuvant Chemotherapy and Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer.
    Antar RM; Xu VE; Adesanya O; Drouaud A; Longton N; Gordon O; Youssef K; Kfouri J; Azari S; Tafuri S; Goddard B; Whalen MJ
    Curr Oncol; 2024 May; 31(5):2566-2581. PubMed ID: 38785473
    [No Abstract]   [Full Text] [Related]  

  • 6. Laparoscopic pelvic lymph node dissection system based on preoperative primary tumour stage (T stage) by computed tomography in urothelial bladder cancer: results of a single-institution prospective study.
    Yuan JB; Zu XB; Miao JG; Wang J; Chen MF; Qi L
    BJU Int; 2013 Jul; 112(2):E87-91. PubMed ID: 23323729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer.
    Larcher A; Sun M; Schiffmann J; Tian Z; Shariat SF; McCormack M; Saad F; Fossati N; Abdollah F; Briganti A; Buffi N; Graefen M; Guazzoni G; Montorsi F; Karakiewicz PI
    Eur J Surg Oncol; 2015 Mar; 41(3):353-60. PubMed ID: 25477269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival.
    Lenis AT; Lec PM; Michel J; Brisbane W; Golla V; Sharma V; Gollapudi K; Blumberg J; Chamie K
    Urol Oncol; 2020 Oct; 38(10):796.e7-796.e14. PubMed ID: 32446641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in pelvic lymph node dissection in invasive bladder cancer: A Dutch nationwide population-based study during centralization of care.
    Hermans TJ; Fransen van de Putte EE; Fossion LM; Werkhoven EV; Verhoeven RH; van Rhijn BW; Horenblas S
    Urol Oncol; 2016 Dec; 34(12):532.e7-532.e12. PubMed ID: 27491835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.
    Antar RM; Xu VE; Farag CM; Lucero J; Drouaud A; Sundaresan V; Gordon OF; Azari S; Wynne M; Smith AK; Whalen MJ
    Transl Androl Urol; 2024 Aug; 13(8):1349-1363. PubMed ID: 39280687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping.
    Bochner BH; Cho D; Herr HW; Donat M; Kattan MW; Dalbagni G
    J Urol; 2004 Oct; 172(4 Pt 1):1286-90. PubMed ID: 15371825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer.
    Sodagum L; Passarelli R; Pfail J; Patel HV; Chua K; Doppalapudi SK; Golombos D; Elsamra SE; Singer EA; Jang TL; Srivastava A; Ghodoussipour S
    Urol Oncol; 2024 Jan; 42(1):21.e9-21.e20. PubMed ID: 37953186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
    Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
    Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends of Lymph Node Outcomes in Partial Cystectomy for Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Klose C; Gordon O; Sparks A; Whalen M
    Clin Genitourin Cancer; 2023 Dec; 21(6):703-709. PubMed ID: 37336704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes.
    Mistretta FA; Cyr SJ; Luzzago S; Mazzone E; Knipper S; Palumbo C; Tian Z; Nazzani S; Saad F; Montanari E; Tilki D; Briganti A; Shariat SF; de Cobelli O; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Apr; 18(2):129-137.e3. PubMed ID: 32001182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
    von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD
    Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    Cha EK; Sfakianos JP; Sukhu R; Yee AM; Sjoberg DD; Bochner BH
    BJU Int; 2018 Oct; 122(4):627-632. PubMed ID: 29633530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.